Zobrazeno 1 - 10
of 50
pro vyhledávání: ''
Autor:
G.L. De Salvo, G. Moretti, Patricia Galván, Maria Vittoria Dieci, Giancarlo Bisagni, R. Vicini, Gaia Griguolo, Giulia Bianchi, Aleix Prat, Massimo Ambroggi, Tomás Pascual, Laia Paré, Loredana Urso, Antonio Frassoldati, Carlo Alberto Giorgi, Pierfranco Conte, Enrico Orvieto, Valentina Guarneri
Publikováno v:
Annals of Oncology
Background In human epidermal growth factor receptor 2 (HER2+) breast cancers, neoadjuvant trials of chemotherapy plus anti-HER2 treatment consistently showed lower pathologic complete response (pCR) rates in hormone receptor (HR) positive versus neg
Autor:
David Miles, Bongin Yoo, A. Fung, Sarah Heeson, Yunjoo Im, Michael S. Beattie, Adam Knott, Sandra M. Swain
Publikováno v:
Annals of Oncology. 28:2761-2767
Combination pertuzumab, trastuzumab, and docetaxel (D) is considered standard first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. This post hoc, exploratory analysis of CLEOPATRA study data evalu
Autor:
Emmanouil Saloustros, Nikolaos Ziras, S. Kakolyris, V. Georgoulias, Nikolaos K. Kentepozidis, D. Mavroudis, N. Malamos, Athanasios Athanasiadis, P. Katsaounis, I. Boukovinas, P. Papakotoulas, Alexios Matikas
Publikováno v:
Annals of Oncology. 27:1873-1878
Background: Sequential administration of anthracycline and taxane is the current standard of care adjuvant regimen for node-positive early breast cancer. Due to long-term toxicity concerns, anthracycline-free regimens have been developed. We compared
Autor:
John Crown, Vincent Houe, Vladimir Semiglazov, S. Bensfia, John R. Mackey, A. Chan, Mary-Ann Lindsay, Louise Provencher, Miguel Martín, Michael F. Press, Wolfgang Eiermann, S. Sehdev, Guido Sauter, P. Drevot, Tadeusz Pienkowski, M. Buyse, S. Hitier, Mansoor N. Saleh, Saeed Sadeghi
Publikováno v:
Annals of Oncology. 27:1041-1047
Background The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared sequential to concurrent combination of doxorubicin and cyclophosphamide with docetaxel chemotherapy in women with node-positive non-metastatic breast ca
Publikováno v:
Annals of Oncology. 27:608-618
Background Guidelines recommend primary prophylaxis (PP) with granulocyte-colony-stimulating factors (G-CSF) for patients above a febrile neutropenia (FN) risk threshold of 20%. Practitioners often use FN rates of regimens based on data from randomiz
Autor:
José Baselga, E.S. Lowe, Begoña Graña, Judy Garber, Judith Balmaña, P. Frewer, Eric P. Winer, Nadine Tung, Cristina Saura, Steven J. Isakoff, Paula D. Ryan
Publikováno v:
Annals of Oncology. 25:1656-1663
Background To establish the maximum tolerated dose, determine safety/tolerability and evaluate the pharmacokinetics and preliminary efficacy of olaparib in combination with cisplatin in patients with advanced solid tumors. Patients and methods Patien
Autor:
Michel Marty, Véronique Diéras, M. Lau, Howard A. Burris, M. DeSilvio, John Crown, M. Espie, P. Tresca, D. Kothari, M.J. Kennedy, Kevin M. Koch
Publikováno v:
Annals of Oncology. 24:2005-2011
Background This phase IB, open-label, dose-escalation study evaluated the safety, tolerability, and optimally tolerated regimen (OTR) of lapatinib in combination with docetaxel and trastuzumab in patients with previously untreated stage IV metastatic
Autor:
Valérie Rigau, William Jacot, Olivier Dereure, Didier Bessis, Nicolas Kluger, Bernard Guillot, S. Poujol, Gilles Romieu, Eric Frouin
Publikováno v:
Annals of Oncology. 23:2879-2884
Background To analyze the clinical and histological features of permanent alopecia following a sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel regimen for adjuvant breast cancer treatment. Patients and methods Women treated fo
Publikováno v:
Annals of Oncology. 23:305-311
Over the last 35 years, classical CMF (combination chemotherapy with cyclophosphamide, methotrexate and fluorouracil) has been a milestone in the adjuvant treatment of women with breast cancer. However, after an early burst of success lasted just ove
Autor:
Eric P. Winer, Julie Najita, Pamela J. DiPiro, Harold J. Burstein, Nan Lin, Ian E. Krop, Erin M. Olson
Publikováno v:
Annals of Oncology. 23:93-97
Background Women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) can respond to multiple lines of anti-HER2 therapy. It is unknown whether these patients will derive further clinical benefit following trea